Pyridoxal dependent epilepsy (Q41204): Difference between revisions

From determinar.ia.br - Determine suas informações
Created a new Item
 
Changed label, description and/or aliases in pt-br, en
description / pt-brdescription / pt-br
 
A epilepsia dependente de piridoxal-5-fosfato geralmente se apresenta com crises epilépticas neonatais intratáveis ​​e é diagnosticada por análise do líquido cefalorraquidiano (LCR), teste genético e resposta clínica. A maioria dos pacientes tem mutações causadas pelo gene da piridoxamina 5'-fosfato oxidase (PNPO). O diagnóstico precoce e o tratamento eficaz podem levar a um resultado de neurodesenvolvimento relativamente favorável.
description / endescription / en
 
Pyridoxal 5-phosphate dependent epilepsy usually presents with neonatal intractable seizures and is diagnosed by cerebrospinal fluid (CSF) analysis, gene testing, and clinical response. The majority of patients have pyridoxamine 5'-phosphate oxidase (PNPO) gene disease causing mutations. Early diagnosis and effective treatment can lead to a relatively favourable neurodevelopmental outcome.

Revision as of 07:16, 13 August 2026

Pyridoxal 5-phosphate dependent epilepsy usually presents with neonatal intractable seizures and is diagnosed by cerebrospinal fluid (CSF) analysis, gene testing, and clinical response. The majority of patients have pyridoxamine 5'-phosphate oxidase (PNPO) gene disease causing mutations. Early diagnosis and effective treatment can lead to a relatively favourable neurodevelopmental outcome.
Language Label Description Also known as
default for all languages
8A61.00
    English
    Pyridoxal dependent epilepsy
    Pyridoxal 5-phosphate dependent epilepsy usually presents with neonatal intractable seizures and is diagnosed by cerebrospinal fluid (CSF) analysis, gene testing, and clinical response. The majority of patients have pyridoxamine 5'-phosphate oxidase (PNPO) gene disease causing mutations. Early diagnosis and effective treatment can lead to a relatively favourable neurodevelopmental outcome.

      Statements